Pharmacokinetic evaluation of eltoprazine

@article{Wigal2011PharmacokineticEO,
  title={Pharmacokinetic evaluation of eltoprazine},
  author={S. Wigal and Sophie Duong},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2011},
  volume={7},
  pages={775 - 781}
}
Introduction: Approvals and availability of drugs and delivery systems to treat attention-deficit/hyperactivity disorder (ADHD) have increased steadily in the last decade. The development of new pharmacological agents to treat ADHD symptoms in adults allows for both single and combination therapy for optimal efficacy. Eltoprazine hydrochloride, a serotonergic agent currently under development, is the focus of the current paper. Areas covered: This paper provides an overview of the… Expand
Mavoglurant as a treatment for Parkinson’s disease
Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia
Treatments and compositions for attention deficit hyperactivity disorder: a patent review
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
CLINICAL TRIAL HIGHLIGHTS – DYSKINESIA

References

SHOWING 1-10 OF 38 REFERENCES
Non–stimulant medications in the treatment of ADHD
Dose-proportionality of eltoprazine. Pharmacokinetics of single oral doses in healthy subjects.
NEUROCHEMICAL PROFILE OF ELTOPRAZINE
Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder
  • J. Barton
  • Medicine
  • Archives of Disease in Childhood
  • 2005
BEHAVIOURAL PHARMACOLOGY OF THE SERENIC, ELTOPRAZINE
Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
The Neuropsychopharmacology of Attention-Deficit/Hyperactivity Disorder
  • S. Pliszka
  • Medicine, Psychology
  • Biological Psychiatry
  • 2005
Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration.
...
1
2
3
4
...